The 2022 Tandem Meetings | COVID-19 vaccination in patients with B-cell malignancies after CAR-T therapy
Saurabh Dahiya, MD, University of Maryland School of Medicine, Baltimore, MD, shares the results of a study investigating immunogenicity to COVID-19 vaccination in patients with B-cell malignancies who have received CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study reported that only one of 18 patients was able to mount an antibody immune response demonstrating significant neutralization against COVID-19 antigens. Further analysis revealed that these patients were able to mount an immune response against common infections, suggesting that patients with B-cell malignancies treated with CD19-directed CAR-T therapy can only mount an immune response against previous antigens. Results on T-cell immunogenicity to COVID-19 vaccination are eagerly awaited. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
